Announcements

Job offersmore »

Tweeting Growers

Top 5 - yesterday

Top 5 - last week

Top 5 - last month

Exchange ratesmore »




Inocucor accelerates commercialization with $9.5 million investment

Inocucor uses a patented fermentation process to combine multi-strains of bacteria, yeasts and fungi into powerful biostimulants that naturally improve crop yields, shorten growing periods and create healthier, more resilient soils for farmers and greenhouse growers. A suite of microbial biocontrol products that target devastating diseases in potatoes, tomatoes and strawberries is also under development.

“We’ve come a long way in a few short years, with two products in use in the field, a signature line of biocontrol products under development and hundreds of field trials underway throughout the Americas,” said Inocucor’s President and CEO Donald R. Marvin. “Our business strategy and plan are guided by our vision for a Second Green Revolution for agriculture, one that uses earth-friendly farming products to improve crop yields, revitalize soils and improve water quality.”

Early next spring, Inocucor will occupy its new 30,000-square-foot U.S. headquarters and commercialization office currently under construction in Centennial, Colo. Its Montreal-based, R&D-focused Technical Center of Excellence is currently being enlarged from 10,000 to 20,000 square feet to house expanded product development and manufacturing operations. The company employs about 40 people in Montreal and the U.S., and anticipates adding another 25 to 30 high-level scientific and managerial professionals over the next year.

$9.5 million funding
Inocucor Corporation announced the $9.5 million USD ($12.1M CAD) second close of its Series B financing round. Funds raised to date in its Series B round now total $38.5 million USD ($50.9 million CAD).

The round was led by Pontifax AgTech, a growth capital investor in the global food and agriculture sector.

Other participants in the second Series B round include existing investors Cycle Capital Management (Montreal), Desjardins Innovatech (Montreal) and Cairn Investments (Denver). Inocucor’s first Series B equity financing of $29 million USD ($38.8 million CAD) in March 2017 was led by TPG ART with participation from existing investors.

Funds will enable Inocucor to accelerate its commercialization activities, through the increased production and marketing of its first- and second-generation biostimulant products, Synergro and Synergro Free. They will also advance development of a new suite of biocontrol products that combat economically devastating diseases in high-value crops such as strawberries, tomatoes and potatoes.

For more information
Inocucor


Publication date: 1/9/2018

 


 

Other news in this sector:

8/16/2018 Rabobank: EUR 1,698 million net profit in first half 2018
8/16/2018 Full Harvest closes $8.5 million Series A to solve food waste problem
8/16/2018 Illumitex expands to Canada
8/16/2018 CAN (SK): David Marit becomes provincial agriculture minister
8/15/2018 Pete's Living Greens names Brian Cook as President
8/15/2018 Oboya board member decides to resign
8/15/2018 Village Farms reports net loss, cannabis production ramps up
8/15/2018 Future Farm announces strategic financing, new corporate secretary
8/14/2018 UK: BASIS celebrates its 40th anniversary
8/14/2018 Dr. Hong Zhu promoted to Senior VP of R&D at BioConsortia
8/13/2018 "Investing in consumer trust pays off in the end"
8/13/2018 US (HI): Kilauea Community Agricultural Center continues to grow
8/13/2018 UK: Ebtech Group celebrates 10 years
8/13/2018 RHP certification for Nestaan
8/10/2018 NL: New test facility for NovaCropControl
8/10/2018 UK: Horticulture specialist joins AHDB Board
8/10/2018 UK: Assessing financial needs of your horticultural business
8/9/2018 25 years of Belgian truss tomatoes
8/9/2018 Tanimura & Antle hires Don Klusendorf
8/9/2018 Former Motorola CIO joins Syngenta